esketamine
Articles tagged with “esketamine”
CBT After Esketamine Boosts Depression Outcomes in Trial
A new randomized trial finds that adding 16 weeks of CBT after esketamine significantly improves depression and suicidal ideation compared to esketamine alone.
Side Effects & Dropout Rates: New Data on Ketamine for TRD
New clinical guidance on NMDA antagonist side effects and dropout rates offers practical insight for patients considering ketamine therapy for TRD.
Why Patients Quit NMDA Therapy—And What Providers Should Do
New clinical review urges faster dose optimization and earlier switching between NMDA therapies for treatment-resistant depression. Here's what it means for patients.
When to Push for Stronger TRD Treatments, Per Experts
Psychiatric Times highlights underuse of highly effective TRD treatments. Here's what this means if you or a loved one is stuck in a cycle of failed antidepressants.
NMDA Side Effects: What Dropout Rates Mean for Patients
New clinical guidance on NMDA antagonist side effects and dropout rates offers practical insights for patients considering ketamine or esketamine therapy.
Ketamine Side Effects: What New Clinical Data Reveals
New clinical analysis examines side effect profiles and discontinuation rates for ketamine and esketamine. Here's what treatment-resistant depression patients should know.
Ketamine Side Effects: What New Data Tells Patients
A new clinical review examines side effect profiles and discontinuation rates for NMDA antagonists like ketamine and esketamine. Here's what patients should know.
Ketamine Side Effects: What New Data Means for Patients
New clinical guidance on NMDA antagonist side effects and discontinuation rates gives patients and families sharper questions to ask before starting ketamine therapy.
How Doctors Choose Ketamine vs. Other TRD Treatments
New clinical guidance explains how psychiatrists choose between esketamine, ketamine, and brain stimulation for treatment-resistant depression patients.
Esketamine's Role in Treatment-Resistant Depression Care
Where esketamine (Spravato) sits in 2026 treatment-resistant depression care: FDA-approved indications, response rates after SSRI failure, access barriers, and how it compares to generic IV and at-home options.
Generic Ketamine vs Spravato: Comparing Off-Label and FDA-Approved Options
Side-by-side comparison of generic racemic ketamine and Spravato (esketamine) nasal spray: per-session cost, insurance coverage, FDA approval status, and what generic availability looks like in 2026.
What a Spravato (Esketamine) Nasal Spray Session Is Really Like
Curious what a Spravato (esketamine) session is really like? A patient walks through the spray, the 2-hour monitoring, and the comedown sensations.
Need help or want to reach readers?
Have a correction, provider question, or advertising inquiry? Reach the editorial team.